Mayne Pharma Group (ASX:MYX) said the consultation period initiated by Cosette Pharmaceuticals under their scheme implementation deed has expired without Cosette issuing a termination notice, according to a Wednesday filing with the Australian bourse.
In February, the company said it entered a scheme implementation deed (SID) to be acquired by Cosette via a scheme of arrangement for AU$7.40 per share.
On May 17, Cosette issued a notice triggering a 10-day good-faith consultation period under the SID, citing a material adverse change.
Mayne Pharma rejected the claim, stating no such change occurred and all relevant disclosures had been made. While Cosette has not terminated the deal, it signaled it may do so if the issue remains unresolved.
The company said the expiry of the period does not prevent Cosette from terminating the deal.
Mayne also confirmed receipt of a close-out letter from the US Food and Drug Administration, stating that the company has addressed previous regulatory concerns.
Shares of the company rose past 4% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.